CD49b, CD87, and CD95 Are Markers for Activated Cancer-Associated Fibroblasts Whereas CD39 Marks Quiescent Normal Fibroblasts in Murine Tumor Models.
CD39
CD49b
CD87
cancer-associated fibroblasts
normal fibroblasts
subcutaneous 4T1 mouse tumor model
subcutaneous CT26.WT mouse tumor model
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2019
2019
Historique:
received:
29
04
2019
accepted:
18
07
2019
entrez:
21
8
2019
pubmed:
21
8
2019
medline:
21
8
2019
Statut:
epublish
Résumé
Fibroblasts are thought to be key players in the tumor microenvironment. Means to identify and isolate fibroblasts as well as an understanding of their cancer-specific features are essential to dissect their role in tumor biology. To date, the identification of cancer-associated fibroblasts is widely based on generic markers for activated fibroblasts in combination with their origin in tumor tissue. This study was focused on a deep characterization of the cell surface marker profile of cancer-associated fibroblasts in widely used mouse tumor models and defining aberrant expression profiles by comparing them to their healthy counterparts. We established a generic workflow to isolate healthy and cancer-associated fibroblasts from solid tissues, thereby reducing bias, and background noise introduced by non-target cells. We identified CD87, CD44, CD49b, CD95, and Ly-6C as cancer-associated fibroblast cell surface markers, while CD39 was identified to mark normal fibroblasts from healthy tissues. In addition, we found a functional association of most cancer-related fibroblast markers to proliferation and a systemic upregulation of CD87, and CD49b in tumor-bearing mice, even in non-affected tissues. These novel markers will facilitate the characterization of fibroblasts and shed further light in their functions and implication in cancer progression.
Identifiants
pubmed: 31428583
doi: 10.3389/fonc.2019.00716
pmc: PMC6690267
doi:
Types de publication
Journal Article
Langues
eng
Pagination
716Références
Annu Rev Genet. 1999;33:29-55
pubmed: 10690403
Eur J Biochem. 2001 Jan;268(2):364-73
pubmed: 11168371
Drug Resist Updat. 1999 Apr;2(2):85-90
pubmed: 11504475
Nat Rev Cancer. 2002 Apr;2(4):277-88
pubmed: 12001989
J Interferon Cytokine Res. 2002 Jul;22(7):799-806
pubmed: 12184918
Cancer Cell. 2003 May;3(5):439-43
pubmed: 12781361
Immunity. 2004 Feb;20(2):231-42
pubmed: 14975244
Oncogene. 2004 Apr 12;23(16):2950-66
pubmed: 15077156
Oncogene. 2004 Apr 29;23(20):3732-6
pubmed: 15077180
EMBO J. 2004 Aug 4;23(15):3175-85
pubmed: 15272306
Nat Rev Cancer. 2004 Nov;4(11):839-49
pubmed: 15516957
Lung Cancer. 2004 Aug;45 Suppl 2:S163-75
pubmed: 15552797
Respir Res. 2005 Apr 17;6:37
pubmed: 15833141
Biochim Biophys Acta. 2005 May 25;1755(1):25-36
pubmed: 15907590
Nat Rev Cancer. 2006 May;6(5):392-401
pubmed: 16572188
Cancer Biol Ther. 2006 Dec;5(12):1640-6
pubmed: 17106243
Immunology. 2007 Apr;120(4):502-11
pubmed: 17343612
J Immunol. 2007 May 1;178(9):5552-62
pubmed: 17442937
Blood. 2007 Aug 15;110(4):1225-32
pubmed: 17449799
Cancer Biol Ther. 2007 Apr;6(4):618-9
pubmed: 18027438
J Clin Invest. 1991 Oct;88(4):1067-72
pubmed: 1833420
Curr Opin Genet Dev. 2009 Feb;19(1):67-73
pubmed: 19211240
Nat Rev Cancer. 2009 Apr;9(4):285-93
pubmed: 19308068
Am J Pathol. 2009 Jul;175(1):190-200
pubmed: 19497996
Semin Cell Dev Biol. 2010 Feb;21(1):19-25
pubmed: 19857592
Exp Cell Res. 2010 May 1;316(8):1324-31
pubmed: 20211171
Nature. 2010 May 27;465(7297):492-6
pubmed: 20505730
Mol Cancer. 2010 Jun 23;9:161
pubmed: 20573240
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Neoplasia. 2011 Mar;13(3):206-16
pubmed: 21390184
Purinergic Signal. 2011 Jun;7(2):231-41
pubmed: 21484085
J Cell Biol. 1990 Aug;111(2):783-92
pubmed: 2166055
Cancer Metastasis Rev. 2012 Jun;31(1-2):195-208
pubmed: 22101652
In Vivo. 2012 Jul-Aug;26(4):571-6
pubmed: 22773570
Immunity. 2012 Dec 14;37(6):1076-90
pubmed: 23219392
Trends Mol Med. 2013 Jun;19(6):355-67
pubmed: 23601906
Theranostics. 2013 Jun 25;3(7):487-95
pubmed: 23843896
Clin Cancer Res. 2013 Nov 1;19(21):5914-26
pubmed: 24052018
Stem Cells. 2014 Jan;32(1):145-56
pubmed: 24395741
Biomark Res. 2014 Jan 07;2(1):1
pubmed: 24398220
Cancer Res. 2015 Jan 1;75(1):73-85
pubmed: 25368021
Cell Death Differ. 2015 Apr;22(4):549-59
pubmed: 25656654
Front Immunol. 2015 May 06;6:201
pubmed: 25999946
PLoS One. 2015 Jun 08;10(6):e0127948
pubmed: 26053043
Thromb Haemost. 2016 May 2;115(5):1001-9
pubmed: 26791370
Cancer Cell. 2016 Nov 14;30(5):668-681
pubmed: 27846389
Cancer Med. 2017 Feb;6(2):463-470
pubmed: 28097809
J Exp Med. 2017 Mar 6;214(3):579-596
pubmed: 28232471
Immunol Rev. 2017 Mar;276(1):121-144
pubmed: 28258700
Int J Cancer. 1988 May 15;41(5):707-12
pubmed: 2835323
Eur J Immunol. 1988 Nov;18(11):1819-26
pubmed: 2849552
Trends Cancer. 2016 Dec;2(12):736-746
pubmed: 28741520
PLoS One. 2017 Jul 27;12(7):e0182039
pubmed: 28750018
Biochimie. 1987 Apr;69(4):315-20
pubmed: 2888493
Cancer Cell. 2018 Mar 12;33(3):463-479.e10
pubmed: 29455927
Front Oncol. 2018 Feb 12;8:24
pubmed: 29484286
Hum Pathol. 2018 Sep;79:1-8
pubmed: 29555579
Cell Commun Adhes. 2018 Dec;24(1):11-18
pubmed: 29734861
Front Immunol. 2018 Jun 18;9:1358
pubmed: 29967610
Cancer Discov. 2019 Feb;9(2):282-301
pubmed: 30366930
J Cell Physiol. 2019 Jun;234(6):8274-8285
pubmed: 30378132
Clin Cancer Res. 2019 Apr 1;25(7):2194-2205
pubmed: 30385653
Oncogene. 2019 Jul;38(27):5339-5355
pubmed: 30936458
Immunology. 1977 Jul;33(1):101-7
pubmed: 68924
Eur J Immunol. 1981 Aug;11(8):597-603
pubmed: 7274325
Lancet. 1994 Nov 26;344(8935):1470-2
pubmed: 7526103
Lancet. 1995 Mar 11;345(8950):615-9
pubmed: 7534855
Cancer Res. 1995 May 1;55(9):1831-5
pubmed: 7537174
Nat Med. 1995 Jun;1(6):558-63
pubmed: 7585123
Am J Pathol. 1994 Jun;144(6):1269-80
pubmed: 8203466
Biochem Biophys Res Commun. 1996 Sep 4;226(1):247-53
pubmed: 8806622
J Exp Med. 1996 Dec 1;184(6):2141-51
pubmed: 8976170
Int J Cancer. 1997 Jul 3;72(1):1-22
pubmed: 9212216
Leukemia. 1997 Nov;11(11):1833-41
pubmed: 9369415
Nature. 1998 Dec 17;396(6712):699-703
pubmed: 9872321